NCT01011725View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

March 31, 2009

Conditions
Osteoporosis
Interventions
DRUG

MK 0773

25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks

DRUG

Placebo

Placebo oral tablet b.i.d for 12 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01011725 - Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003) | Biotech Hunter | Biotech Hunter